The objectives of the study is to describe axitinib therapy management through use of the data to be generated by ConcertAI
not mandatory
Study Type
OBSERVATIONAL
Pfizer Inc.
New York, New York, United States
To describe type of immune related adverse events and adverse events related to axitinib
describe type of immune related adverse events and adverse events related to axitinib
Time frame: during treatment period
To describe the percentage of patients with documentation of dose modifications
describe dose modifications
Time frame: during treatment period
To describe the percentage of patients with usage of concomitant high-dose corticosteroid
descriptive assessment
Time frame: during treatment period
To describe the percentage of patients alive at pre-specified time points (6 months, 12 months, 18 months, 24 months) from start of the index therapy
calculation of overall survival time
Time frame: during study period
To estimate the best overall response (partial response, complete response, progressive disease, or stable disease
description of overall response
Time frame: during treatment period
To estimate time to treatment discontinuation
calculation of duration of treatment
Time frame: during treatment period
To estimate PFS
calculation of progression free survival
Time frame: during treatment period
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.